Get started
Author

F Baert

Observed names: Baert, F., F BAERT, F. Baert, F. J. Baert
Institution: AZ Delta
OpenAlex ID: A5022158321
Clustering of increased small intestinal permeability in families with Crohn's disease
1997 · M Peeters, B Geypens, et al. · Gastroenterology · 262
PDF
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women
2013 · N. Pedersen, A. Bortoli, et al. · Alimentary Pharmacology & Therapeutics · 190
PDF
Yersiniosis: The Clinical Spectrum
1994 · F. Baert, W. Peetermans, et al. · Acta Clinica Belgica · 18
HACA formation after infliximab (Remicade™) treatment in Crohn's disease is clearly associated with infusion reactions
2001 · M NOMAN, F BAERT, et al. · Gastroenterology · 14
O08 Concomitant Immunosuppression Does Not Impact on the Outcome of Maintenance Infliximab Therapy in Crohn's Disease: Final Results of the Imid Trial
2007 · G. Van Assche, G. Paintaud, et al. · Journal of Crohn s and Colitis Supplements · 13
PDF
New Strategies In The Management Of Inflammatory Bowel Disease.
1999 · P. Rutgeerts, F. Baert · Acta Clinica Belgica · 11
The presence and severity of neural inflammation predict severe postoperative recurrence of Crohn's disease
1998 · G. D'Haens, S. Colpaert, et al. · Gastroenterology · 10
Bilateral Hilar Lymphadenopathy Associated with Yersinia enterocolitica Infection
1994 · F. Baert, D. Knockaert, et al. · Clinical Infectious Diseases · 9
DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
2018 · S Berends, M Löwenberg, et al. · Journal of Crohn s and Colitis · 8
Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
2015 · S Vermeire, E Louis, et al. · PubMed · 8
PDF
Abrikossoff Cell Tumor of the Oesophagus: a Case Report and Review of the Literature
2008 · F. Marolleau, F. Baert, et al. · Acta Clinica Belgica · 7
Immunomodulator Therapy of Inflammatory Bowel Disease.
1997 · F. Baert, P. Rutgeerts. · Acta Clinica Belgica · 4
TNF-alpha antibody therapy causes a fast and dramatic decrease of histologic colonic inflammation in Crohn's disease but not in ulcerative colitis
1996 · F Baert, G. D'Haens, et al. · Gastroenterology · 4
P274 Factors driving treatment escalation in Crohn’s disease in the CALM trial
2018 · W Reinisch, R Panaccione, et al. · Journal of Crohn s and Colitis · 3
Switching intravenous to subcutaneous infliximab was safe and successful during 1-year follow up in Ulcerative Colitis and Crohn patients – a Belgian single center experience
2025 · L Cornelis, E De Jonckere, et al. · Acta gastro-enterologica belgica · 1
PDF
P0756 Etrasimod efficacy in patients with mildly to moderately active Ulcerative Colitis (modified Mayo score 4–6) in the phase 3 ELEVATE UC clinical programme
2025 · A J Yarur, G R D'Haens, et al. · Journal of Crohn s and Colitis · 1
PDF
Health literacy, quality of life, work productivity and activity impairment in young adults with Crohn's disease compared to diabetes mellitus patiënts: longterm follow-up from the Belgian Crohn's Disease Registry.
2019 · Constance Carels, Lucas Wauters, et al. · 1
A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM
2017 · Colombel Jf, Remo Panaccione, et al. · The American Journal of Gastroenterology · 1
Confirmation of the importance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease
1998 · M. Peeters, S. Vermeire, et al. · Gastroenterology · 1
Presence of pANCA in Crohn's patients with ''UC-like'' clinical, phenotype is related to disease activity
1997 · Marc Peeters, Paul Rutgeerts, et al. · Gastroenterology · 1
P0972 Higher vedolizumab clearance associates with poor therapeutic outcomes during maintenance therapy of vedolizumab in Crohn’s disease
2025 · S Anjie MD, G R A M D’Haens, et al. · Journal of Crohn s and Colitis
PDF
P0748 Characterisation of Remission Levels in Patients with Ulcerative Colitis Treated with 5-Aminosalicylates: Results of the CARUC-ASA Prospective Multicentre Study
2025 · C Reenaers Dr, C Caenepeel, et al. · Journal of Crohn s and Colitis
PDF
P635 Superior outcomes with early biologic-combination treatment in Crohn’s Disease: Data from an international inception cohort
2020 · M Matheeuwsen, K Vermeijden, et al. · Journal of Crohn s and Colitis
PDF
P250 Correlation of faecal calprotectin levels with Crohn's disease activity scores using two different immunoassays
2014 · M. Oyaert, D. De Smet, et al. · Journal of Crohn s and Colitis
P550 Diagnosing and treating pediatric Crohn's disease patients: is there a difference between adult and pediatric gastroenterologists’ practices? Results of the BELCRO cohort
2013 · E. De Greef, B. Maus, et al. · Journal of Crohn s and Colitis
Works count: 33
Citation count: 567
H-index: 8
I10-index: 7
Year
Topic
Type